CAS 1202757-89-8: AVL-292

Description: AVL-292, also known as a selective inhibitor of Bruton's tyrosine kinase (BTK), is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications in treating various hematological malignancies and autoimmune diseases. As a BTK inhibitor, AVL-292 works by disrupting the signaling pathways that are crucial for the survival and proliferation of B cells, which are often implicated in these conditions. The compound is characterized by its ability to selectively bind to the BTK enzyme, thereby inhibiting its activity without significantly affecting other kinases, which helps to minimize off-target effects. AVL-292 has undergone various preclinical and clinical studies to evaluate its efficacy and safety profile. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its therapeutic potential. Overall, AVL-292 represents a promising avenue for targeted therapy in diseases driven by aberrant B cell signaling.

Synonyms:

• 2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-
• N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide
• AVL292

N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide

CAS: 1202757-89-8

• Formula: C₂₂H₂₂FN₅O₃
• Purity: %
• Color and Shape: Solid
• Molecular weight: 423.4402

Spebrutinib

CAS: 1202757-89-8

Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with …

• Formula: C₂₂H₂₂FN₅O₃
• Purity: 100% - 97.02%
• Color and Shape: Solid
• Molecular weight: 423.44

CC 292

CAS: 1202757-89-8

Inhibits non-receptor tyrosine kinase BTK; antineoplastic

• Formula: C₂₂H₂₂FN₅O₃
• Purity: Min. 95%
• Molecular weight: 423.44 g/mol